drugset / Trial / NCT06849401
The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
Phase 0
Not yet recruiting
9 enrolled
Shanghai Jiao Tong University School of Medicine
Shanghai Vitalgen BioPharma Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
To learn if the VGO-Cs01p can help to control CD7-positive relapsed/refractory acute T-lymphoblastic leukemia (R/R T-ALL) in children.
Timeline
- Start
- 2025-07
- Primary completion
- 2026-08
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VGO-Cs01p | Cell therapy | 4e+07 cells/kg | — |
| Subject | VGO-Cs01p | Cell therapy | 1.2e+08 cells/kg | — |
| Subject | VGO-Cs01p | Cell therapy | 3.6e+08 cells/kg | — |